1996

Forest Laboratories Statement Regarding Flu Prevention Options Following Recent Vaccine Recall: PR Newswire, 24 December 1996.; NEW YORK, Dec. 23 /PRNewswire/ -- Forest Laboratories, Inc. (AMEX: FRX), in response to a recent government report recommending antivirals be considered as a flu prevention alternative, announced today that it s prepared to meet potentially increased demands for its product Flumadine. Flumadine, an antivira1 medication
Philadelphia AIDS Consortium: Gross Mismanagement in $12 Million PA Health Department Contract: PR Newswire, Monday, December 23, 1996 8:33 AM EDT.; PHILADELPHIA, Dec. 23 /PRNewswire/ -- The following statement was issued today by The Philadelphia AIDS Consortium: A group of community leaders called for the Commonwealth of Pennsylvania to rescind a $12 million contract with Benova, Inc., the corporation hired to enroll a11 persons eligible for Medicaid in managed c
Agouron Files New Drug Application for Anti-HIV Drug Viracept(R): PR Newswire, Monday, December 23, 1996 - 9:00 AM EDT.; LA JOLLA, Calif., Dec. 23 /PRNewswire/ -- Agouron Pharmaceuticals Inc today announced it has submitted to the U.S. Food and Drug Administration ( FDA ) a New Drug Application (NDA) covering its anti-HIV drug VIRACEPT(R) (nelfinavir mesylate). Agouron is the first company to petition FDA for simultaneous approval of its
Pharmacia & Upjohn and Gilead Sciences Receive European Recommendation for Vistide: PR Newswire, Friday 20 December 1996.; LONDON and FOSTER CITY, Calif., Dec. 20 /PRNewswire/ -- Pharmacia & Upjohn , Inc. (NYSE: PNU), and Gilead Sciences , Inc. (Nasdaq: GILD), announced today that the Committee for Proprietary Medicinal Products (CPMP) has recommended that Vistide (R) (
Trinity Biotech Submits One-Step HIV Test for Physician's Office to FDA: PR Newswire, 19 December 1996.; DUBLIN, Ireland , Dec. 19 /PRNewswire/ -- Trinity Biotech (Nasdaq: TRIBY) today announced that it has submitted its Uni-Gold HIV test to the U.S. Food and Drug Administration ( FDA ). Trinity s Uni-Gold HIV test is a simple, easy to use, one-step test which has been submitted to the FDA for approval for use in a
ALRT Receives FDA Clearance to Launch Phase I/IIA Trials of ALRT1550: PR Newswire, 19 December 1996.; SAN DIEGO, Dec. 19 /PRNewswire/ -- Allergan Ligand Retinoid Therapeutics, Inc. (ALRT) (Nasdaq: ALRIZ) today announced that it has received clearance from the Food and Drug Administration to launch Phase I/IIa clinical trials for the treatment of advanced cancers with ALRT1550 capsules, a new investigational anti-cancer
SciClone Pharma Rome ZADAXIN Trial Results Strong: PR Newswire, 19 December 1996.; SAN MATEO, Calif., Dec. 19 /PRNewswire/ -- SciClone Pharmaceuticals, Inc., an international biopharmaceutical company, today reported that its lead product, ZADAXIN(R) thymosin alpha 1, achieved strong results in a hepatitis C trial led by Dr. Guido Rasi of the Institute of Experimental Medicine in Rome.
NanoSystems and Merck & Co., to Investigate a New Formulation of Protease Inhibitor, Indinavir, For Treatment of Pediatric HIV Patients: PR Newswire, Thursday December 19 8:47 AM EDT; COLLEGEVILLE, Pa., Dec. 19 /PRNewswire/ -- NanoSystems LLC today announced an agreement with Merck & Co. , Inc. to collaborate on the evaluation of an experimental NanoCrystal(TM) formulation of Merck s HIV protease inhibitor, indinavir, for the treatment of HIV in pediatric patients and other special patient group
On-Line Consumers Say `No' to Additional FDA Control of Clinical Trials Information on the Internet; Internet Ranks First for On-Line Patients: PR Newswire, Wednesday, 18 December 1996.; BOSTON, Dec. 18 /PRNewswire/ -- In a survey released today, researchers at CenterWatch found that consumers and patients unanimously voted against additional FDA review for clinical trials already approved for Internet listing by an Institutional Review Board (IRB). Survey respondents also said that the Internet is the
IGEN Licenses HIV-1 p7 Capsid Assay From National Institutes of Health; Potential New Marker of AIDS Progression: PR Newswire, 18 December 1996.; GAITHERSBURG, Md., Dec. 18 /PRNewswire/ -- IGEN International, Inc. (Nasdaq: IGEN) announced today that it has obtained worldwide rights to a novel immunoassay for detection and quantitation of human immunodeficiency virus (HIV-1) from the U.S. National Institutes of Health (NIH). IGEN intends to develop the test for c
Caring For Babies With AIDS To Benefit From A / X Armani Exchange's `Giving Never Goes Out of Style' Holiday Campaign: PR Newswire, 18 December 1996.; LOS ANGELES, Dec. 18 /PRNewswire/ -- CARING FOR BABIES WITH AIDS, the only organization of its kind dedicated to providing residential, direct care and outreach services to HIV/AIDS affected children and families living in Los Angeles, has been selected by A / X ARMANI EXCHANGE of Santa Monica, CA as recipients of its
Stadtlanders Pharmacy to Acquire Castro Village; Pharmacies Focus on Specialized HIV/AIDS Pharmacy Care: PR Newswire, 18 December 1996.; PITTSBURGH, Dec. 18 /PRNewswire/ -- Stadtlanders Pharmacy announced today the execution of a definitive agreement to purchase Castro Village Pharmacies, with locations in Los Angeles and San Francisco, from ValueRx. Stadtlanders is a provider of disease-specific pharmaceutical care to tens of thousands of individuals l
Neurobiological Technologies, Inc. Starts Phase II Memantine Trial With NIH Aids Unit; Potential Treatment For AIDS-Related Dementia and Nerve Damage: PR Newswire, Wednesday, 18 December 1996.; RICHMOND, Calif., December 18, 1996 -- Neurobiological Technologies, Inc. (Nasdaq: NTII) today announced that the Adult AIDS Clinical Trials Group (AACTG) has initiated a Phase II clinical trial of NTII s neuroprotectant Memantine, an orally administered NMDA receptor antagonist. The trial will evaluate Memantine s abi
Paracelsian Announces Preliminary Results of Safety Study Show AndroVir(TM) Well Tolerated with Decreases in HIV Viral Load and Rapid Increases in CD4 Positive Cells: PR Newswire, Thursday December 12 10:34 AM EDT.; ITHACA, N.Y., Dec. 12 /PRNewswire/ -- Paracelsian Inc today announced preliminary results of its initial human safety trial of AndroVir(TM) in HIV-positive subjects conducted by Bastyr University. Bastyr is a College of Natural Medicine (Naturopathy) located in Seattle, Washington, that studies natural products through
MedImmune Files IND To Begin Human Clinical Trials For First Preventative Human Papillomavirus Vaccine Candidate: PR Newswire, Wednesday, 11 December 1996.; GAITHERSBURG, Md., Dec. 11 /PRNewswire/ -- MedImmune, Inc. (Nasdaq: MEDI) today announced it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration ( FDA ) to initiate human clinical trials with a vaccine for the prevention of human papillomavirus (
Advanced Viral Research Reports on Clinical Results of RETICULOSE in Patients With AIDS: PR Newswire, Tuesday, 10 December 1996.; NEW YORK, Dec. 10 /PRNewswire/ -- Advanced Viral Research Corp today announced preliminary results of a clinical trial of its peptide nucleic acid drug RETICULOSE in patients with AIDS. The double-blind, randomized, placebo-controlled clinical trial is being conducted at The Queen Elizabeth Hospital, University of the
Medical Discoveries Announces Preliminary Test Results Confirming MDI-P As Potential Antifungal Agent: PR Newswire, 10 December 1996.; SALT LAKE CITY, Dec. 10 /PRNewswire/ -- Medical Discoveries, Inc. (OTC Bulletin Board: MLSC) today announced successful test results evaluating the potential of its proprietary multipurpose antimicrobial agent, MDI-P (Medical Discoveries Inc.(Pharmaceutical), against Candida albicans, a pathogenic yeast/fungus, that co
Investigators Present Interim Phase I/II Data on Targretin(TM) (LGD1069) Topical in Cutaneous T-Cell Lymphoma at American Society of Hematology Conference; 41% of Patients Achieve Partial or Complete Response: PR Newswire, 9 December 1996.; SAN DIEGO, Dec. 9 /PRNewswire/ -- Debra Breneman, MD, Associate Professor of Clinical Dermatology and Director of Dermatopharmacology at the University of Cincinnati, today reported to the medical scientific community at the American Society of Hematology Conference, interim results of Phase I/II clinical trials for th
IDEC Pharmaceuticals And Genentech Announce Positive Final Results For Pivotal Phase III Trial Of IDEC-C2B8 As Single Agent; Results Of Phase II Combination Trial Also Reported: PR Newswire, 9 December 1996.; ORLANDO, Dec. 9 /PRNewswire/ -- IDEC Pharmaceuticals Corporation (Nasdaq: IDPH) and Genentech , Inc. (NYSE: GNE) have announced positive final results from a pivotal Phase III trial of IDEC-C2B8 as a single agent therapy for relapsed low grade or follicular non-Hodgkin s lymphoma . The tria
Elizabeth Taylor Visits Needle Exchange Site in New York City To Show Support for Needle Exchange to Reduce Transmission of HIV: PR Newswire, Monday December 9 1996 7:30 AM EDT; NEW YORK, Dec. 9 /PRNewswire/ -- In an unscheduled visit, Elizabeth Taylor dropped in to visit staff and clients of the Lower East Side Harm Reduction Center on Thursday, December 5 in Manhattan. Together with hairdresser Jose Eber and Joe Spellman, the Executive Vice President for Elizabeth Arden, the actress arrived
Philadelphia AIDS Consortium Leads Executive Directors In Civil Disobedience to Stop HealthChoices: PR Newswire, 6 December 1996.; PHILADELPHIA, Dec. 6 /PRNewswire/ -- Philadelphia AIDS Consortium Executive Director Larry Hochendoner announced today that he and Board President Joe Cronauer (Executive Director of We the People Living with HIV/AIDS) invited the Executive Directors of AIDS service organizations to join them on Tuesday, December 10 at
Dallas Nonprofit Wins National Housing Award: PR Newswire, Thursday December 5 1996 - 9:27 AM EDT; MIAMI, Dec. 5 /PRNewswire/ -- AIDS Services of Dallas, a Dallas nonprofit housing developer, is among six community-based nonprofits to receive the first Metropolitan Life Foundation Award for Excellence in Affordable Housing in the category of supportive housing. The $15,000 award, will be presented at The Enterprise
INTERNET alfredo Cybercafe to host the website launch of controversial AIDS researcher Peter Duesberg - WWW.DUESBERG.COM: PR Newswire, Wednesday December 4 1996 - 5:18 PM EDT; SAN FRANCISCO--(BUSINESS WIRE)--Dec. 4, 1996--Peter Duesberg Website Launch Dec. 9, 1996, 10:00 a.m. INTERNET alfredo. 790-A Brannan Street, San Francisco Peter Duesberg, Berkeley biologist-errant, who enraged AMA officials by opposing the belief that HIV causes AIDS, will be on hand at INTERNET alfredo for the launch
SciClone Pharmaceuticals Launches ZADAXIN(R) Thymosin Alpha 1 in the People's Republic of China; Follows Presentation of ZADAXIN Hepatitis B Data at National Meeting of Liver Specialists: PR Newswire, Wednesday, 4 December 1996.; SAN MATEO, Calif., Dec. 4 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN), an international biopharmaceutical company, announced today that it has launched ZADAXIN(R) thymosin alpha 1 in the People s Republic of China as a treatment for chronic hepatitis B .
SyStemix Plans to Initiate Gene Therapy Trials for HIV Infection: PR Newswire, Wednesday, 4 December 1996.; PALO ALTO, Calif., Dec. 4 /PRNewswire/ -- SyStemix, Inc. (Nasdaq: STMX) today announced that the FDA has accepted SyStemix Investigational New Drug (IND) application to initiate a Phase I/II gene therapy trial for treatment of HIV-infected patients. According to the trial protocol, a therapeutic gene (Rev M10) will be
Schering-Plough Files Patent Infringement Suit Against Amgen on INFERGEN: PR Newswire, Wednesday, 4 December 1996.; MADISON, N.J., Dec. 4 /PRNewswire/ -- Schering Corporation, a subsidiary of Schering-Plough Corporation (NYSE: SGP) has filed suit against Amgen Inc. of Thousand Oaks, Calif., charging that Amgen s manufacture and use of its consensus interferon product INFERGEN infringes U.S. Patent No. 4,530,901 held by Biogen Inc.
Plans Announced to Suspend Admissions at the Personal Care Facility for Persons Living with AIDS Located in West Mt. Airy; Skilled Nursing to Remain Open at Girard Medical Center - Personal Care to Close: PR Newswire, Tuesday, 3 December 1996.; PHILADELPHIA, Dec. 3 /PRNewswire/ -- Today, the City of Philadelphia s Health Department and Mercy Health Corporation of Southeastern Pennsylvania, announced that the West Mt. Airy personal care home for persons living with AIDS is no longer able to accept admissions in order to eventually close the personal care home.
Priority Pharmacy Selected as Nationwide Distributor for New Breakthrough AIDS Drug Serostim(TM): PR Newswire, Tuesday, 3 December 1996, 1:39 P.M.; SAN DIEGO, Dec. 3 /PRNewswire/ -- Priority Pharmacy, a leading source of HIV- and AIDS-related medications and information, has been chosen as one of six nationwide distributors of the new breakthrough AIDS drug Serostim (TM), announced David C. Zeiger, president and CEO of the nationwide home-delivery pharmacy that in
SeroCare Program Provides Support for People Treated with Serostim, Human Growth Hormone (rDNA origin), for AIDS Wasting; SeroCare(TM) Designed to Facilitate Both Access to Serostim(TM) and Successful Management of AIDS Wasting: PR Newswire, Monday, 2 December 1996.; NORWELL, Mass., Dec. 2 /PRNewswire/ -- The SeroCare(TM) Program, a comprehensive assistance package to benefit both physicians and people with AIDS wasting, was launched today by Serono Laboratories, Inc. SeroCare includes a unique cost containment program, a national network of specialty pharmacy distributors, reimbur
UNAIDS and WHO Report Acknowledges Importance of Female Condom for HIV/AIDS Prevention; Female Health Company Has Public Sector Price Agreement with UNAIDS: PR Newswire, Monday, 2 December 1996, 8:31 A.M. EDT; CHICAGO, Dec. 2 /PRNewswire/ -- The Female Health Co announced that it has signed a three-year agreement with the Joint United Nations Programme on HIV/AIDS ( UNAIDS ) to provide a global public sector price for the female condom. The agreement, based on worldwide demand, enables each of the program s 160 U.N. member s
Isis Publication Demonstrates Antisense Inhibition of RNA Metabolism Through A Novel Mechanism: PR Newswire, Monday, 2 December 1996.; CARLSBAD, Calif., Dec. 2 /PRNewswire/ -- Isis Pharmaceuticals (Nasdaq: ISIP) has demonstrated that antisense compounds can work through a novel mechanism of RNA splicing, inhibiting a key step in RNA metabolism and the production of disease-causing proteins. In an article published in the November 29, 1996 issue of Jo
Cartoon Condom Helps Fight AIDS: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday, 29 November 1996.; SEATTLE, Nov. 29 /PRNewswire/ -- PATH (Program for Appropriate Technology in Health), an international, nonprofit organization headquartered in Seattle, has developed a unique computer program designed to help teach condom use. The software, How To Use A Condom Correctly, runs on a 386 or faster PC and is designed to g
UNAIDS and WHO Report Acknowledges Importance of Female Condom In HIV/AIDS Prevention: Female Health Company Signs Public Sector Price Agreement with UNAIDS: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 28 November 1996, 6 A.M. EST; ADVANCE/ LONDON, Nov. 28 /PRNewswire/ -- The Female Health Co today announced that it has signed a three-year agreement with the Joint United Nations Programme on HIV/AIDS ( UNAIDS ) to provide a global public sector price for the female condom. The agreement, based on worldwide demand, enables each of the program s 19
White House Will Dim Lights to Observe World AIDS Day: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 27 November 1996 5:43 PM EDT; WASHINGTON, Nov. 27 /PRNewswire/ -- On Sunday, December 1, the White House will dim its lights for fifteen minutes, between 7:45 and 8:00 p.m., to observe World AIDS Day and to offer a tribute to those infected and affected by HIV/AIDS. Villages, towns and cities across the country will join the White House as a visual
VA Advances in HIV Research and Treatment Benefit All: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 26 November 1996.; WASHINGTON, Nov. 26 /PRNewswire/ -- The Department of Veterans Affairs (VA) health care system, the nation s single largest source of direct care to AIDS and HIV-infected patients, has advanced clinical care and treatment of this population by integrating research with patient care. Veterans with HIV infection receive
Retailer Fights AIDS: Raises Money And Awareness For World AIDS Day-- Every Day Almost 6,000 People Are Newly Infected With HIV, The Virus Which Causes AIDS. -- American Association for World Health.: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 25 November 1996 11:25 AM EDT; WAKE FOREST, N.C., Nov. 25 /PRNewswire/ -- Although it may not make the daily headlines anymore, the AIDS crisis is not going away. It is estimated that by the year 2000, 110 million people will be infected by HIV, the virus that causes AIDS*. And there is still no cure in sight. What can we do to stop the spread of AI
'God's Love We Deliver' To Receive Sara Lee Foundation Leadership Award: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 25 November 1996 10:03 AM EDT; CHICAGO, Nov. 25 /PRNewswire/ -- God s Love We Deliver (GLWD), a meal-delivery service for New York City-area residents who are confined to their homes by AIDS-related illnesses, will receive the 1996 Sara Lee Foundation Leadership award, Michael E. Murphy, Sara Lee Foundation president, announced today. A presentation
Pediatric Aids Foundation Funds HIV Prevention Program For Youth: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 25 November 1996 - 8:03 A.M.; LOS ANGELES, Nov. 25 /PRNewswire/ -- In keeping with its leadership role on issues pertaining to pediatric HIV/AIDS, the Pediatric AIDS Foundation announces concurrent with World AIDS Day, December 1, the funding of The Fernwood Project, a national demonstration project for youth HIV education and prevention. The progr
The Gravest Show on Earth: America in the Age of Aids: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 20 November 1996.; NEW YORK, Nov. 20 /PRNewswire/ -- Author Elinor Burkett, in her book The Gravest Show On Earth: America In The Age Of Aids, published by Picador, is scathing in her criticism of all the major players in the AIDS crisis, including politicians, the scientists, the drug companies, the gay activists, and the black communit
New Symbol of Hope for HIV/AIDS Supporters: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 20 November 1996.; FERNDALE, Mich., Nov. 20 /PRNewswire/ -- The Midwest AIDS Prevention Project (MAPP) is proud to present INFINITY, the new symbol of hope in the fight against the spread of HIV/AIDS. This one of a kind jewelry emblem can only be described as a masterpiece. Its intricate design and symbolism breathe new life into the str
Planned Parenthood Applauds Institute of Medicine's Call For National Campaign To Fight Epidemic of Sexually Transmitted Infections: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 20 November 1996.; WASHINGTON, Nov. 20 /PRNewswire/ -- Planned Parenthood Federation of America President Gloria Feldt announced today that the nationally-known family planning organization applauds and strongly supports the recommendations of the Institute of Medicine to launch an aggressive campaign to fight sexually transmitted infect
Marinol Found Promising in Treatment of Geriatric Patients with Alzheimer's: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 19 November 1996.; WASHINGTON, Nov. 19 /PRNewswire/ -- Unimed Pharmaceuticals, Inc. (Nasdaq: UMED) today announced that results of a preliminary study, suggesting Marinol(R) (dronabinol) may be useful in the treatment of anorexia as well as disturbed behavior and mood in geriatric patients with Alzheimer s disease, were presented here at
Protein Design Labs Announces Start of a Multinational Phase II Trial in Chronic Hepatitis B Infection: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 19 November 1996.; MOUNTAIN VIEW, Calif., Nov. 19 /PR Newswire/ -- Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI) today announced that Boehringer Mannheim GmbH, a collaborative partner of the Company, has initiated a multinational Phase II clinical trial of PDL s Human Anti-Hepatitis B Antibody in patients with chronic
Protein Design Labs/G.BOE Begin Hepatitis Trial: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 19 November 1996.; MOUNTAIN VIEW, Calif., Nov. 19 /PR Newswire/ -- Protein Design Labs, Inc. (PDL) today announced that Boehringer Mannheim GmbH, a collaborative partner of the Company, has initiated a multinational Phase II clinical trial of PDL s Human Anti-Hepatitis B Antibody in patients with chronic
Research May Yield Information About how the HIV Virus Produces AIDS: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 18 November 1996.; LOS ANGELES, Nov. 18 /PRNewswire/ -- Edward Gomperts, M.D., a researcher at Childrens Hospital Los Angeles (CHLA), was one of several co-authors of an article recently published by the prestigious journal Science. The study titled Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of th
Public Health Community Calls on President Clinton and 105th Congress to Support the HIV/AIDS Agenda; During American Public Health Association Conference in New York City: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 18 November 1996.; WHO: Dr. Scmakula Kiwanuka, Ambassador of Uganda to the United Nations, Dr. Helen Gayle, Director of the Center for HIV, STD, and TB Prevention at the Centers for Disease Control and Prevention, Umberto Cruz, Director of the Division of HIV Health and Community Services at the AIDS Institute, and Ronald Johnson,
Hidden 'Second Structure' Critical in Aids Virus Attack; Warner-Lambert and Leukosite Form Collaboration to Discover Drugs That Block the Chemokine Receptor Portion of the HIV Infection Pathway: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 13 November 1996.; CAMBRIDGE, Mass., Nov. 13 /PRNewswire/ -- Before the AIDS virus can invade a cell, it must pair with a first receptor, then change shape to expose a second structure that binds to a second receptor, it was reported in the November 14 issue of Nature. This discovery, by scientists at LeukoSite, Inc. (Cambridge, Mass.),
Philadelphia AIDS Consortium: HealthChoices Offers No Choices; HMO Squanders Tax Dollars for People With AIDS; Unable to Refer Patients to AIDS Specialists: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 13 November 1996.; PHILADELPHIA, Nov. 13 /PRNewswire/ -- The Philadelphia AIDS Consortium issued the following: An estimated 60 percent of people living with HIV/AIDS in the region currently rely on Medical Assistance for their healthcare. A broad coalition of people with HIV/AIDS, AIDS service organizations and advocates (see list below
Japanese Patent Office Issues Patent To CEL-SCI Corporation On AIDS Diagnostic Kit: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 13 November 1996; ALEXANDRIA, Va., Nov. 13 /PRNewswire/ -- CEL-SCI CORPORATION (Nasdaq: CELI) announces today that the Japanese Patent Office has issued a patent on the diagnostic use of CEL-SCI s HGP-30 technology in AIDS. Japan constitutes one of the largest pharmaceutical markets in the world and is a major gateway into Asia, an area
SciClone Pharmaceuticals Reports Statistically Significant U.S. Hepatitis C Trial Data Using ZADAXIN(R) Thymosin Alpha 1 at Annual Liver Disease Meeting: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 12 November 1996.; SAN MATEO, Calif., Nov. 12 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN), reported today that the results of its 103 patient randomized, double-blind and placebo-controlled U.S. chronic hepatitis C trial were presented by the principal investigator, Kenneth Sherman, M.D., Ph.D., of the University of Cin
Unimed Pharmaceuticals Announces NTZ Phase II/III Trial With AIDS Clinical Trials Group: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 12 November 1996.; BUFFALO GROVE, Ill., Nov. 12 /PRNewswire/ -- Unimed Pharmaceuticals, Inc. (Nasdaq: UMED) today announced that the AIDS Clinical Trials Group (ACTG), a cooperative supported by the National Institute of Allergy and Infectious Diseases, will conduct a Phase II/III placebo controlled study of nitazoxanide (NTZ) to treat A
Aronex Reports Preliminary Clinical Results on its HIV Integrase Inhibitor, Zintevir(TM): PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 12 November 1996.; THE WOODLANDS, Texas, Nov. 12 /PRNewswire/ -- Aronex Pharmaceuticals, Inc. (Nasdaq/NNM: ARNX) today reported preliminary results from Phase I trials of Zintevir(TM), the first of a new class of HIV integrase inhibiting compounds, in HIV-positive patients. Based upon these results, Aronex is planning follow-on multiple
A Leading Antiviral, Famvir, is Safe and Effective Treatment for Hepatitis B: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Saturday, 11 November 1996.; CHICAGO, Nov. 11 /PRNewswire/ -- Results from a large, multi-national, dose finding study show that the antiviral agent Famvir(R) (famciclovir, SmithKline Beecham) is effective in the treatment of chronic hepatitis B with a safety profile comparable to placebo. The study provides clear evidence that famciclovir acts q
Celgene Corporation Reconfirms Plans to Submit NDAs For Use of Thalidomide in Leprosy and AIDS Cachexia: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday 11 November 1996.; WARREN, N.J., Nov. 11 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG) today reconfirmed that it will submit a New Drug Application (NDA) by the end of 1996 with the Food and Drug Administration for the use of thalidomide in the treatment of erythema nodosum leprosem (ENL), a disorder associated with leprosy. The
QIAGEN Acquires Key Patent Portfolio in Nucleic Acid Separation for Research and Clinical Diagnostics: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday, 8 November 1996.; AMSTERDAM, The Netherlands , Nov. 8 /PRNewswire/ -- QIAGEN N.V., (Nasdaq: QGENF) today announced it has acquired a technology platform for DNA and RNA purification and stabilization of samples such as clinical specimens using cationic detergents, from the Iowa Biotechnology Corporation and the University of Iowa. Under
Drug with Active Marijuana Ingredient Available Through Medical Channels: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 6 November 1996.; BUFFALO GROVE, Ill., Nov. 6 /PRNewswire/ -- Unimed Pharmaceuticals, Inc. (Nasdaq: UMED) today announced that, despite the passage of proposition 215 to make marijuana legal for medicinal purposes in California and a similar proposal in Arizona, a pure synthetic formulation of marijuana s active ingredient THC is availa
INCSTAR Corp. Gets FDA Okay For Diagnostic Tests: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 6 November 1996.; MINNEAPOLIS, Nov. 6 /PRNewswire/ -- INCSTAR Corporation announced today that it has received 510(k) clearance to market its second generation tests for the detection of the infectious diseases, rubella, cytomegalovirus ( CMV ) and herpes simplex .
Researchers Report For The First Time In Science How Tumor Cancer Cells Survive And Adapt To Chemotherapy Research Demonstrates that Inhibition of Specific Signaling Protein Can Facilitate Cell Death: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 5 November 1996.; SAN DIEGO, Nov. 5 /PRNewswire/ -- Researchers published three studies in the current issue of the journal Science (vol. 274, issue 5288) that for the first time show how tumor cells survive and adapt to chemotherapy. Cells die by a process called apoptosis, or programmed cell death, which can be induced by agents such
Ameritech Survey Shows AIDS, Employment, Education Chief Concerns of Midwest Teens; Students Disenchanted With Politics and Politicians: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 4 November 1996.; CHICAGO, Nov. 4 /PRNewswire/ -- AIDS, future employment prospects, education and the current political process are the top concerns of Midwest high school students, according to results disclosed today of the Ameritech Long Distance LearningLink Student Survey. The survey was conducted among 2,857 students at four high
'Linda's Meals': the Home Delivered Meals Program of AIDS Partnership Michigan: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 4 November 1996.; DETROIT, Nov. 4 /PRNewswire/ -- AIDS Partnership Michigan is pleased to announce the launch of Michigan s first hot-meal home delivery program for homebound people with AIDS. The program, which began delivering meals on Monday, October 21, 1996, will initially focus on the areas of metro Detroit with the highest concen
Roxane Acquires The Rights To Duraclon From Fujisawa: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 4 November 1996.; DEERFIELD, Ill., Nov. 4 /PRNewswire/ -- Fujisawa USA , Inc. and Roxane Laboratories Inc. announced today that Roxane has acquired the NDA and all rights to Duraclon(TM) (clonidine HCl), a new treatment for severe pain in cancer patients. The FDA has granted marketing clearance of Dura
FDA Clears Oral Cytovene for Prevention of CMV Disease In Solid Organ Transplant Recipients: PR Newswire, Tuesday, 3 November 1996.; NUTLEY, N.J., Dec. 3 /PRNewswire/ -- Hoffmann-La Roche announced today that the company has received clearance from the Food and Drug Administration ( FDA ) to market oral ganciclovir (Cytovene(R) capsules) for the prevention of cytomegalovirus ( CMV
Vertex Pharmaceuticals Researchers Report Three-Dimensional Structure of p38 Mitogen-activated Kinase: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday, 1 November 1996; CAMBRIDGE, Mass., Nov. 1 /PRNewswire/ -- Researchers from Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) have solved the three-dimensional atomic structure of p38 mitogen-activated protein (MAP) kinase, a human enzyme that regulates key cytokines involved with inflammation and programmed cell death. The discovery i
CEL-SCI CORPORATION Announces Interim Results of HGP-30 AIDS Vaccine Study: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 31 October 1996.; ALEXANDRIA, Va., Oct. 31 /PRNewswire/ -- In response to multiple investor inquiries, CEL-SCI CORPORATION (Nasdaq: CELI) announces interim results of its Phase I safety study with the HGP-30 AIDS vaccine in HIV infected individuals. AIDS ReSearch Alliance, a non-profit AIDS research organization located in West Hollywoo
The Immune Response Corporation Announces Clinical Trial in Spain Using REMUNE(TM): PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 31 October 1996.; CARLSBAD, Calif., Oct. 31 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that the Ministry of Health of the Autonomous Government of Madrid, Spain will be conducting a Phase II combination therapy clinical trial using REMUNE and antiviral drugs for the treatment of HIV infection.
Biogen Announces That U.K. House Of Lords Rules That British Hepatitis B Patent Is Invalid: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 31 October 1996.; CAMBRIDGE, Mass., Oct. 31 /PRNewswire/ -- Biogen, Inc. (Nasdaq: BGEN) today announced that the House of Lords in the United Kingdom has ruled that one of its two British patents for hepatitis B antigens is invalid. The decision of the House of Lords affirms an October 1994 ruling of the United Kingdom s Cou
Spanish Health Ministry To Conduct Trial/Treat HIV: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 31 October 1996; CARLSBAD, Calif., Oct. 31 /PRNewswire/ -- The Immune Response Corporation announced today that the Ministry of Health of the Autonomous Government of Madrid, Spain will be conducting a Phase II combination therapy clinical trial using REMUNE and antiviral drugs for the treatment of HIV infection.
Scientific Advisory Group On Education (S A G E) To Develop Global 'Train the Trainer' And Outreach Program For Female Condom: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 29 October 1996.; CHICAGO, Oct. 29 /PRNewswire/ -- With the goal of integrating balanced, accurate information about the female condom throughout all levels of safer sex education, a working group comprising public health professionals from the U.S. and the U.K. met for the second time on Oct. 21-22. The Scientific Advisory Group on Edu
Pediatric AIDS Foundation Co-Founder Susan DeLaurentis to Serve on the Office of AIDS Research Advisory Council, National Institutes of Health: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 29 October 1996.; SANTA MONICA, Calif., Oct. 28 /PRNewswire/ -- The Pediatric AIDS Foundation announced today that its Co-Founder and Chief Executive Officer Susan DeLaurentis has been invited to serve on the Office of AIDS Research Advisory Council (OARAC), National Institutes of Health, for a two-year term. The invitation came directl
Agouron To Submit NDA For Anti-HIV Drug VIRACEPT: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 24 October 1996.; LA JOLLA, Calif., Oct. 24 /PRNewswire/ -- Agouron Pharmaceuticals, Inc., today announced that it will proceed promptly to assemble and file with the U.S. Food and Drug Administration ( FDA ) a New Drug Application (NDA) seeking approval to commence marketing of the company s HIV protease inhibitor VIRACEPT(TM) (nelfina
Nationwide Search Launched For Young People Involved in Fight Against HIV/AIDS: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 23 October 1996; WASHINGTON, Oct. 23 /PRNewswire/ -- A nationwide search has been launched to identify young people who have chosen to become involved in the fight against AIDS, and who exemplify the highest standards of volunteerism and community service as a result of their involvement. Twenty young people between the ages of 12 and
Agouron Makes Discovery/Helps Anti-viral Research: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday, 18 October 1996; LA JOLLA, Calif., Oct. 18 /PRNewswire/ -- Agouron Pharmaceuticals, Inc., today announced that its scientists have solved the three- dimensional atomic structure of the protease enzyme encoded by the human hepatitis C virus (HCV). HCV is a virus that causes illness that ranges from a mild flu-like disease t
Protein Design Labs Signs Patent Licensing and Humanization Agreement With Fourth Japanese Company: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 21 October 1996; MOUNTAIN VIEW, Calif., Oct. 21 /PRNewswire/ -- Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI) announced today that it has signed an agreement to humanize a mouse monoclonal antibody for a Japanese company. Under the terms of the agreement, the Japanese company will have a non-exclusive license under PDL s patents relat
Vertex Pharm Publishes Paper On Hepatitis Drug: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday, 18 October 1996.; CAMBRIDGE, Mass., Oct. 18 /PRNewswire/ -- Researchers from Vertex Pharmaceuticals Incorporated have solved the three-dimensional atomic structure of the hepatitis C virus NS3 protease, an enzyme that plays a key role in viral replication. The achievement is described in a paper, Crystal Structure of the Hepatitis C Vi
Italian Researchers Report Statistically Significant Results in Hepatitis B Trial Using Thymosin Alpha 1: Second Study Also Reports Strong Results for Thymosin Alpha 1 in Combination with Low Dose Natural Alpha Interferon for Treatment of Hepatitis B: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 15 October 1996.; SAN MATEO, Calif., Oct. 15 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN), an international biopharmaceutical company, reported today that its lead product, thymosin alpha 1, achieved statistically significant results in the treatment of chronic hepatitis B in a multicenter, randomized and
Universal Studios Florida To Host Public Display Of AIDS Memorial Quilt: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 15 October 1996; ORLANDO, Fla., Oct. 15 /PRNewswire/ -- More than 500 fabric panels from the AIDS Memorial Quilt will soon be on public display at Universal Studios Florida. Representing AIDS victims from the southeastern U.S., the quilt display at Universal is in recognition of World AIDS Day on December 1 and follows the October 11-1
The Immune Response Corporation Announces Expanded Access Program of REMUNE(TM) to Treat HIV Infection: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 14 October 1996; CARLSBAD, Calif., Oct. 14 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that the Food and Drug Administration ( FDA ) has granted allowance for an expanded access program to satisfy the increasing level of patient demand for REMUNE. The expanded access program is designed to provide REM
Celgene Corporation Completes Pivotal Clinical Trial for Thalidomide in AIDS Patients: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 8 October 1996; WARREN, N.J., Oct. 8 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG) announced successful completion of its pivotal Phase II/III clinical trial of Synovir(R) (thalidomide) for severe weight loss (cachexia) associated with HIV infection, the virus which causes AIDS. The company anticipates that it will announce resul
Study Shows Famvir Safe and Effective for Suppression of Recurrent Genital Herpes in HIV-Infected Individuals: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 8 October 1996; LAS VEGAS, Oct. 8 /PRNewswire/ -- Famciclovir (Famvir(R), SmithKline Beecham) is safe, well-tolerated and effective in significantly suppressing herpes simplex virus-2 (HSV-2) outbreaks among HIV-infected individuals, according to a recent study conducted at the University of Washington. In the first phase of the stud
Celgene Completes Phase II/III Trial Of Synovir: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 8 October 1996; WARREN, N.J., Oct. 8 /PRNewswire/ -- Celgene Corporation announced successful completion of its pivotal Phase II/III clinical trial of Synovir (thalidomide) for severe weight loss (cachexia) associated with HIV infection, the virus which causes AIDS. The Company anticipates that it will announce results of the trial ea
SmithKline's Study Shows Famvir Reduces Herpes: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 8 October 1996; LAS VEGAS, Oct. 8 /PRNewswire/ -- Famciclovir (Famvir(R), SmithKline Beecham) is safe, well-tolerated and effective in significantly suppressing herpes simplex virus-2 (HSV-2) outbreaks among HIV-infected individuals, according to a recent study conducted at the University of Washington. In the first phase of the stud
The Immune Response Corporation Signs Agreement with Viru-Tech Limited for REMUNE(TM) in South America and Central America: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 8 October 1996; CARLSBAD, Calif., Oct. 8 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that it has agreed to develop and distribute REMUNE in South America and Central America through Viru-Tech Limited ( Viru- Tech ), a privately held company. Under the agreement, Viru-Tech has purchased $3 million of
New Hope in 'New Words': PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 7; WASHINGTON, Oct. 7 /PRNewswire/ -- Many of you will recognize Eric Slocum as news anchor and reporter at KOMO TV in Seattle. Slocum is also a poet with a dream of giving hope to children with AIDS. He has accomplished this by generously offering 100% of the proceeds of the sale of his book, New Words to support pediatr
New Aids Treatment Developed; First Immunology Based Pharmaceutical To Show Successful Treatment of HIV In Advanced AIDS: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 7 October 1996; SHREVEPORT, La., Oct. 7 /PRNewswire/ -- A joint effort between scientists and industry has resulted in the development of a new drug to treat patients in the advanced stages of AIDS. The drug, HRG214, was invented by Dr. Frank Gelder, director of Immunodiagnostic Testing Laboratories, Department of Surgery at Louisiana
U.S. Centers for Disease Control And Prevention Awards SmithKline Beecham Contract for Hepatitis B Adult Vaccine: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday, 4 October 1996; PHILADELPHIA, Oct. 4 /PRNewswire/ -- SmithKline Beecham, distributor of Engerix-B(R) (Hepatitis B Vaccine, Recombinant), today announced that it has been awarded the hepatitis B adult vaccine contract by the U.S. Centers for Disease Control and Prevention (CDC). Hepatitis B is one of the most common preventable inf
A Pro-Family Review of the 104th; `This Congress Took Historic Steps,' Bauer Says: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday, 4 October 1996; WASHINGTON, Oct. 4 /PRNewswire/ -- From defending marriage to fighting for the lives of children killed late in pregnancy to presenting an unprecedented balanced budget with pro-family tax relief, the 104th Congress took historic steps for America s families, said Family Research Council President Gary L. Bauer on Frid
FDA Approves Sale Of Merck Combination Vaccine: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday, 4 October 1996; WEST POINT, Pa., Oct. 4 /PRNewswire/ -- Comvax(TM) (Haemophilus b conjugate (meningococcal protein conjugate) and Hepatitis B (recombinant) vaccine) has been licensed by the U.S. Food & Drug Administration ( FDA ). Developed by Merck & Co. , Inc., it is the first combination product indicated for vaccination of
Merck & Co. Inc.: Comvax (Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine): PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday, 4 October 1996; WEST POINT, Pa., Oct. 4 /PRNewswire/ -- The following was released today by Merck & Co. Inc.: DESCRIPTION COMVAX(TM)* (Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine) is a sterile bivalent vaccine made of the antigenic components used in producing PedvaxHIB(R) (Haemo
Merck & Co., Inc. Receives FDA License To Market Comvax, Combination Vaccine For HIB And Hepatitis B: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday, 4 October 1996; WEST POINT, Pa., Oct. 4 /PRNewswire/ -- Comvax(TM) (Haemophilus b conjugate (meningococcal protein conjugate) and Hepatitis B (recombinant) vaccine) has been licensed by the U.S. Food & Drug Administration ( FDA ). Developed by Merck & Co. , Inc. (NYSE: MRK), it is the first combination product indicated for va
Market Increasing for Rapid Result Diagnostic Tests; Novatek International, Inc.'s Joint Venture Agreements in Latin America Will Benefit Healthcare Systems, Economy: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 2 October 1996; WASHINGTON, Oct. 2 /PRNewswire/ -- Citing the continuing rise in infectious disease statistics throughout the world, Novatek International Inc. s (Nasdaq: NVT) principals outlined the company s tremendous growth potential as exclusive licensees to market and distribute rapid result diagnostic test devices manufactured
Principal Investigator Reports Statistically Significant Results in Randomized and Controlled U.S. Hepatitis C Trial Using ZADAXIN(R) Thymosin Alpha 1: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 2 October 1996; SAN MATEO, Calif., Oct. 2 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) reported today publication of an abstract by the principal investigator of its U.S. randomized, double-blind placebo controlled chronic hepatitis C trial. The abstract reports that the combination of ZADAXIN and alpha interferon dem
Diatide Launches Phase II Trials of Product For Imaging Internal Infections: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 2 October 1996; LONDONDERRY, N.H., Oct. 2 /PRNewswire/ -- Diatide, Inc. (Nasdaq: DITI), which is engaged in developing proprietary radiopharmaceuticals for use in nuclear medicine procedures, has begun Phase II clinical trials of its P483H Techtide, which is intended to provide a new, more effective and safer method of imaging the exa
Cel-Sci In Joint Pact To Evaluate Herpes Peptides: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 1 October 1996; ALEXANDRIA, Va., Oct. 1 /PRNewswire/ -- CEL-SCI CORPORATION (Nasdaq: CELI) and NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE today announce that they have signed a Collaborative Research Agreement to jointly identify and evaluate Herpes Simplex Virus related peptides. This agreement may lead to the future developm
President Signs Medical Patent Bill; Physicians Freed from Threat of New Medical Procedure Patent Lawsuits: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 1 October 1996; FAIRFAX, Va., Oct. 1 /PRNewswire/ -- The American Society of Cataract and Refractive Surgery (ASCRS) announced today that the spending bill passed by the U.S. Senate last night and signed into law by President Clinton provides relief for health care practitioners from the threat of legal action for performing patented
The Immune Response Corporation Receives United States Patent Office Notice of Allowance for Licensed Cancer Technology: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 1 October 1996; CARLSBAD, Calif., Oct. 1 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR), announced today that the United States Patent Office has issued a Notice of Allowance to the Sidney Kimmel Cancer Center ( SKCC ) on a cancer treatment licensed exclusively to Immune Response. The allowed application is entitled Ly
SB's Twinrix Vaccine Receives European Approval; First Combined Hepatitis A+B Vaccine; The Approval Applies To All 15 Countries in the European Union: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; PHILADELPHIA, Sept. 23 /PRNewswire/ -- SmithKline Beecham (NYSE: SBH) (SB) has received approval through the new centralized European registration procedure to market Twinrix, the first combined vaccine against hepatitis A (HAV) and B (HBV). The approval applies to all 15 countries in the European Union.
Clinical Trials Begin For Immucor's Second Automated Blood Analyzer -- The ABS(HV): PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 30 September 1996; NORCROSS, Ga., Sept. 30 /PRNewswire/ -- Immucor, Inc. (Nasdaq: BLUD), maker of blood bank reagent systems and related products, announced today clinical trials for the Company s second automated blood analyzer, the ABS(HV), have begun. Like Immucor s leading instrument, the ABS2000, which was submitted previously to
Report on Progenics' Novel HIV Assay Published in the Journal of Virology; ProSys to be Used in Programs to Discover Inhibitors of HIV Fusion: PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 30 Sep 1996; TARRYTOWN, N.Y., Sept. 30 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. today announced the publication of a scientific paper on Progenics proprietary HIV assay system, ProSys, in the September issue of the Journal of Virology (vol. 17, no. 9). The ProSys system models the earliest steps of the viral life cycle. Prog
Rapid Result HIV Test Matches Western Blot for Accuracy in Head-To-Head Test; ELISA Test Results Wrong: Misdiagnosis of Known HIV Patient Discovered During Test Comparison Survey in Argentina: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; WASHINGTON, Sept. 26 /PRNewswire/ -- As a result of tests run by Novatek International, Inc., the province of Corrientes, Argentina has directed its pharmaceutical company to expedite its agreement with Novatek to manufacture and distribute Novatek s rapid result whole blood diagnostic HIV tests there. A comparison
NABI Granted Japanese Patent for HIV-IG(TM) in Prevention of HIV Transmission; HIV-IG(TM) Currently in Phase III and Phase II Trials with NIH: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; BOCA RATON, Fla., Sept. 27 /PRNewswire/ -- NABI (Nasdaq: NABI) announced today it has received a Japanese patent (Japanese Patent No. 2063902) for HIV- IG(TM), the Company s proprietary HIV immunotherapeutic, as well as the method of producing it. HIV-IG(TM) is one of NABI s lead immunotherapeutic products in developme
HHS Regulations Provide Emergency Access to Promising Therapies: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; WASHINGTON, Sept. 26 /PRNewswire/ -- The Food and Drug Administration and the National Institutes of Health today announced measures designed to protect individuals who may benefit from emergency research. The FDA issued final rules to make it easier for promising experimental drugs and medical devices to be studied in
STC Technologies, Centocor Announce Partnership for Domestic Blood Bank and Plasma Center Industry; Bethlehem-based STC to distribute Centocor's syphilis and CMV test kits: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; BETHLEHEM, Pa., Sept. 25 /PRNewswire/ -- STC Technologies, Inc., a leader in the development of detection technology, today announced a strategic partnership with Centocor Inc. (Nasdaq: CNTO), of Malvern, PA, to provide infectious disease screening kits to blood banks and plasma centers in the
The Immune Response Corporation Announces Publication of REMUNE(TM) Clinical Trial Data: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; CARLSBAD, Calif., Sept. 24 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) published the results of clinical trials using REMUNE in combination with antiviral drug therapy to treat HIV infection in the September issue of the Journal of Clinical Immunology. These trials involved a total of 92 HIV-infected
The Female Health Company Supports Project for Global Public Sector Purchase of Female Condom; Completes Private Placement: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; CHICAGO, Sept. 24 /PRNewswire/ -- The Female Health Company (AMEX: FHC) announced that UNAIDS (in consultation with its relevant partners, WHO, UNFPA, World Bank, USAID, the European Commission and others) in a letter to 193 country affiliates has solicited interest in and requested intended purchase volume for the fem
Trinity Biotech Announces $1.2 Million Contracts for New Adenovirus and Rotavirus Products: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; DUBLIN, Ireland , Sept. 24 /PRNewswire/ -- Trinity Biotech (Nasdaq: TRIBY) today announced the launch of Adenovirus and Rotavirus, two new laboratory based products which detect intestinal related viruses. Trinity has won supply contracts for these products in the United Kingdom ,
FRC Equips Moms and Dads with School Survival Guide, A Tool for Keeping Parents Aware and Involved: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; WASHINGTON, Sept. 24 /PRNewswire/ -- Family Research Council released Tuesday the 1996 Moms and Dad s School Survival Guide, a 64-page resource to help parents stay informed and involved in their children s educational process. Parents today are spending too much time combating condoms, offensive curriculum, and failed
New Xenotransplantation Guideline Available: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; WASHINGTON, Sept. 20 /PRNewswire/ -- The Department of Health and Human Services today proposed a new draft guideline for xenotransplantation -- the transplantation of animal organs and tissue into humans -- aimed at reducing the public health risks while not impeding medical innovation. The recommended procedures anno
Famvir Shows More Effective Antiviral Activity than Valtrex in Preclinical Studies: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; NEW ORLEANS, Sept. 18 /PRNewswire/ -- Results from a recent preclinical study showed that famciclovir (Famvir(R) SmithKline Beecham) is more effective than valacyclovir (Valtrex(R), Glaxo Wellcome ) in preventing recurrence of the Herpes Simplex Virus-Type 1 (HSV-1) after completion of treatment in immunosuppressed mic
New Billboard Urges Los Angeles To Get Hip To Hepatitis, A Deadly Virus: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; LOS ANGELES, Calif., Sept. 18 /PRNewswire/ -- A compelling yellow eye debuts on a new 9-story high billboard on Friday morning, September 20, to warn Southern Californians that five million Americans have hepatitis and asks do you? The billboard is meant to attract attention to the life-threatening dangers of
3-D Structure Of Cytomegalovirus Enzyme Is Published By SmithKline Beecham Scientists; Establishing Structure Of Protease Advances Search For New Antiviral Therapy; Virus Affects Immunocompromised Patients: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; PHILADELPHIA, Sept. 18 /PRNewswire/ -- Scientists from SmithKline Beecham (NYSE: SBH) (SB) have published in the Sept. 19 issue of Nature the three- dimensional atomic structure of an enzyme required for replication of human cytomegalovirus .(1) The research underlying the publication advances efforts to discover new t
The Immune Response Corporation Reports First Interim Analysis of Phase II Clinical Trial Data Using REMUNE(TM) in Thailand by Trinity Medical Group: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; CARLSBAD, Calif., Sept. 17 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today the first interim analysis of the Phase II clinical trial with REMUNE, which is being conducted in Thailand by Trinity Medical Group Co., Ltd. ( Trinity ). This portion of the Phase II trial involved 30 HIV-infecte
Immune Response Reports Early Results Of HIV Drug: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; CARLSBAD, Calif., Sept. 17 /PRNewswire/ -- The Immune Response Corporation announced today the first interim analysis of the Phase II clinical trial with REMUNE, which is being conducted in Thailand by Trinity Medical Group Co., Ltd. ( Trinity ). This portion of the Phase II trial involved 30 HIV-infected individuals,
Oral Ganciclovir Reduces CMV Disease by 79 Percent in Liver Transplant Recipients; Data Presented at ICAAC Meeting Today: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; NEW ORLEANS, Sept. 16 /PRNewswire/ -- Oral ganciclovir (Cytovene(R) capsules), taken for fourteen weeks as preventive therapy, reduced the incidence of potentially life-threatening cytomegalovirus ( CMV ) disease by 79 percent in liver transplant recipients, according to data presented today at the Interscience Confere
Resistance Increasing in Gram-Positive Bacteria; Hospitalizations, Higher Medical Costs and Higher Mortality Rate are Result: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; NEW ORLEANS, Sept. 16 /PRNewswire/ -- Unless swift action is taken, antibiotic-resistant bacteria will become an increasing issue in U.S. hospitals and communities, according to experts presenting at a satellite symposium prior to the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Resear
Phase I/II Clinical Data Reported on Glaxo Wellcome/Vertex HIV Protease Inhibitor: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; NEW ORLEANS, Sept. 16 /PRNewswire/ -- The investigational HIV protease inhibitor 141W94 (VX-478) appears to have significant antiviral activity while also being well-tolerated, according to preliminary data from a small Phase I/II study presented today. 141W94 (VX-478) was discovered at Vertex Pharmaceuticals and is be
First Clinical Data Presented on an Investigational HIV Non-Nucleoside Reverse Transcriptase Inhibitor, DMP 266, Shows Promising Results; Pilot Study Evaluates the Antiviral Activity, Tolerability and Pharmacokinetics of DMP 266 Alone and in Combination with HIV Protease Inhibitor Crixivan (indinavir sulfate): PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; C O R R E C T I O N -- DuPont Merck In First Clinical Data Presented on An Investigational HIV Non- Nucleoside Reverse, moved Monday, September 16, we are advised by the company that the third graph, second line, should read 200 mg, led to a reduction in mean plasma HIV-RNA levels of -1.68 logs + or - 0.50 rather than
Adding Glaxo's Epivir Cuts HIV Progression By 54%: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; NEW ORLEANS, La., Sept. 16 /PRNewswire/ -- A 54 percent reduction in the rate of HIV disease progression or death was observed in patients who added Epivir (R) (lamivudine; 3TC ), rather than adding placebo, to their current treatment regimen, according to a prelimina
Combination of Two Protease Inhibitors Reduces HIV Viral Load by 99.9 Percent: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; NEW ORLEANS, Sept. 16 /PRNewswire/ -- HIV viral load was reduced by 99.9 percent (2.97 logs) with a combination of two protease inhibitors , Abbott Laboratories (NYSE: ABT) Norvir (TM) ( ritonavir ) and Hoffmann-La R
BTG Licenses Gene Therapy Technology to GenVec Inc.: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; GULPH MILLS, Pa., Sept. 16 /PRNewswire/ -- BTG plc (BTG) announced today that it has signed an exclusive worldwide license agreement with GenVec Inc. (GenVec), Rockville, MD, for the development of gene delivery systems based on BTG s Herpes simplex virus ( HSV ) technology. GenVec will develop HSV-based syst
Glaxo Says HIV Drug Phase I/II Study Successful: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; NEW ORLEANS, Sept. 16 /PRNewswire/ -- The investigational HIV protease inhibitor 141W94 (VX-478) appears to have significant antiviral activity while also being well-tolerated, according to preliminary data from a small Phase I/II study presented today. 141W94 (VX-478) was discovered at Vertex Pharmaceuticals and is be
Agouron Announces Expanded Access Program For HIV Protease Inhibitor VIRACEPT(TM): PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; LA JOLLA, Calif., Sept. 16 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. (Nasdaq-NNM: AGPH) today announced the availability of VIRACEPT(TM) (nelfinavir mesylate), an HIV protease inhibitor, through an expanded access program for people with advanced HIV disease who have exhausted all current protease inhibitor treatme
Researchers Present First Preclinical Studies Demonstrating Protection Against HTLV-II Infection: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; NEW YORK, Sept. 13 /PRNewswire/ -- Virologix Corporation announced today that its vaccine candidate for human T cell leukemia virus type II (HTLV-II) was completely effective in animal studies. The results were presented in Baltimore by Dr. William W. Hall at the Annual Meeting of Tumor Cell Biology organized by the In
Conference on Advanced Antisense Chemistries Reports Progress in Attacking Cancer and Viral Diseases 'In Vivo,' Human Trials and Commercial Production Capabilities: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; PARIS, France , Sept. 12 /PRNewswire/ -- Over 200 participants from the U.S., the U.K., Germany , Switzerland , Italy , Denmark , Norway and France gathered at t
AIDS Clinical Trial Group (ACTG) To Conduct Clinical Study of 141W94/VX-478, an HIV Protease Inhibitor: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; CAMBRIDGE, Mass., Sept. 12 /PRNewswire/ -- The AIDS Clinical Trials Group (ACTG), a cooperative group supported by the National Institute of Allergy and Infectious Diseases, will conduct a 24-week Phase II monotherapy study of 141W94/VX-478, an HIV protease inhibitor being developed by Vertex Pharmaceuticals Incorporat
American Academy of Ophthalmology journal report: HIV-Related Orbital Infections Serious, Warrant Early Treatment: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; SAN FRANCISCO, Sept., 12 /PRNewswire/ -- Opportunistic infections of the orbits, or bony sockets that contain the eye globes, result in significant morbidity and mortality, and treatment should be initiated without delay, according to a study in Ophthalmology. Jan W. Kronish, MD, and colleagues from Florida reviewed th
Novavax Reports Successful Transdermal Micellar Nanoparticle Delivery of Testosterone and Progesterone in Preclinical Studies: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; ROCKVILLE, Md., Sept. 11 /PRNewswire/ -- Novavax, Inc. (AMEX: NOX) today reported completion of preclinical testing of testosterone and progesterone in its Micellar nanoparticle ( MNP ) transdermal drug delivery platform. A company spokesman said that peak blood levels of testosterone were approximately three times hig
Salmonella in Eggs on the Rise, but Minnesota Company has a Solution: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; MINNEAPOLIS, Sept. 6 /PRNewswire/ -- Recent media reports, including a USA TODAY article from August 30, 1996, indicate that salmonella poisoning from eggs is on the rise. The federal Centers for Disease Control and Prevention indicated last week that egg transmission has become the most common type of salmonella infec
Agouron Scientists Solve Protease Enzyme Structure: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; LA JOLLA, Calif., Sept. 6 /PRNewswire/ -- Agouron Pharmaceuticals, Inc., today announced that its scientists have solved the three-dimensional atomic structure of the protease enzyme encoded by the human cytomegalovirus ( CMV ). A member of the family of herpes viruses, CMV causes degene
Advanced Viral Research Corp. Announces A Peptide Nucleic Acid (PNA) Human AIDS Trial Underway: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; HALLANDALE, Fla., Sept. 4 /PRNewswire/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) of Hallandale, FL. has received in writing that a double blind clinical AIDS trial assessing the efficacy of the drug Reticulose in human patients with AIDS is currently underway. The study is taking place at the School o
FDA Announces Nationwide Alert on Hallmark Labs Injectable Adrenal Cortex Extract: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; WASHINGTON, Sep. 3 /PRNewswire/ -- The Food and Drug Administration is announcing a nationwide alert concerning 30 milliliter Vials of Hallmark Labs injectable adrenal cortex extract, distributed by Phyne Pharmaceuticals of Scottsdale, Ariz., because this product can cause serious and life-threatening injuries. Since A
Claim Forms Mailed in HIV Class Action Settlement; Eligible Participants Entitled to $100,000: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; PHILADELPHIA, Aug. 30 /PRNewswire/ -- Starting on August 21, thousands of claim forms were mailed to persons with hemophilia who were infected by the AIDS virus, pursuant to the terms of a proposed class action settlement approved by The Honorable John F. Grady, Judge of the United States District Court for the Nort
First Comprehensive Small Animal Model for HIV Dementia is Developed; Considered Major Research Breakthrough: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; OMAHA, Neb., Aug. 28 /PRNewswire/ -- Researchers at the University of Nebraska Medical Center (UNMC) in Omaha have created the first comprehensive small animal model for HIV dementia , a breakthrough that will enable first- time testing of anti-HIV compounds for their ability to penetrate the blood- brain barrier and e
Advanced Viral Announces Publication Of Results Of Study By Shalom Z. Hirschman, M.D.: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; HALLANDALE, Fla., August 28 /PRNewswire/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) of Hallandale, Florida announces that a paper entitled Peptide Nucleic Acids Stimulate Gamma Interferon and Inhibit Replication of the Human Immunodeficiency Virus written by Shalom Z. Hirschman M.D., Professor of Medic
European Commission Grants Final Marketing Authorization For Abbott's Protease Inhibitor For Treatment Of H Infection: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; ABBOTT PARK, Ill., Aug. 27 /PRNewswire/ -- The European Commission, in Brussels, has granted final marketing authorization for Abbott Laboratories protease inhibitor Norvir ( ritonavir ) for treatment of human immunodeficiency virus (HIV) infection and AIDS.
Neurobiological Technologies, Inc. Begins Human Clinical Trials of Memantine: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; RICHMOND, Calif., Aug. 26 /PRNewswire/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) today announced that the company has initiated human clinical trials for Memantine, an orally available NMDA receptor antagonist. Excessive activation of the NMDA receptor on nerve cells plays an important role in producing symp
NAPWA `National CMV Prevention Hotline' Extended; People With AIDS Continue to Seek Facts About Prevalent Opportunistic Infection: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; WASHINGTON, Aug. 26 /PRNewswire/ -- The National Association of People with AIDS (NAPWA) today announced that its confidential, toll-free information line on HIV-related cytomegalovirus ( CMV ) infection is being extended through the end of 1996. In its first six months of operation, the National CMV Prevention Hotli
Serostim, Serono's Human Growth Hormone (rDNA Origin) - PART THREE: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; Kaposi s sarcoma, lymphoma , and other malignancies are common in HIV+ individuals. There was no increase in the incidence of Kaposi s sarcoma, lymphoma, or in the progression of cutaneous Kaposi s sarcoma in clinical studies of Serostim . Patients with internal KS lesions were excluded from
Serostim, Serono's Human Growth Hormone (rDNA Origin) - PART TWO: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; Continued from PR960822 . . . Hepatic Insufficiency: A reduction in r-hGH clearance has been noted in patients with severe liver dysfunction. However, the clinical significance of this in HIV+ patients is unknown. CLINICAL STUDIES The clinical efficacy of Serostim [somatropin (rDNA origin) for
Serostim, Serono's Human Growth Hormone (rDNA Origin) for Aids Wasting, Receives FDA Clearance to Market - PART ONE: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; NORWELL, Mass., Aug. 26 /PRNewswire/ -- For the first time since the AIDS epidemic began, the U.S. Food and Drug Administration ( FDA ) has applied the accelerated review process to a drug which promotes metabolic changes that address the syndrome of AIDS wasting (cachexia), a leading cause of death among people with A
Bailey-Boushay Awarded $750,000 HUD Grant: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; SEATTLE, Aug. 23 /PRNewswire/ -- Bailey-Boushay House will receive a $750,000 capital construction fund award from the federal Housing and Urban Development department. The Bailey-Boushay House is one of only 10 sites nation-wide to receive the award front HUD s HOPWA (Housing Organization for People with AIDS) fund.
NABI Commences Expanded Clinical Program for New H-BIG(R): Formulation for Hepatitis B Prophylaxis Potential for Additional Clinical Indication and Control of all Production Steps: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; BOCA RATON, Fla., Aug. 19 /PRNewswire/ -- NABI (Nasdaq: NABI) today announced the start of an expanded clinical development program for H-BIG(R) (Hepatitis B Immune Globulin [Human] IM 5%), the Company s flagship immunotherapeutic product for prophylaxis of Hepatitis B transmission. Under the program, the Company has i
American Chemical Society Reports on New Category of Anti-Inflammatory Drugs Derived from Thalidomide: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; WASHINGTON, Aug. 19 /PRNewswire/ -- Modifications in the chemical structure of thalidomide by Celgene Corporation (Nasdaq: CELG) have resulted in a novel series of compounds that may be useful for treating a wide range of inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and other condi
Hemophilia Settlement Agreement Approved By Federal Court: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; CHICAGO, Ill., Aug. 15 /PRNewswire/ -- Alpha Therapeutic Corporation, Armour Pharmaceutical Company, Baxter Healthcare Corporation and Bayer Corporation announced today that Judge John F. Grady of the United States District Court for the Northern District of Illinois in Chicago has preliminarily approved a settlement a
Hybridon Begins Clinical Trial of First Advanced Antisense Compound; GEM132 to Target Human Cytomegalovirus: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; WORCESTER, Mass., Aug. 15 /PRNewswire/ -- Hybridon, Inc. (Nasdaq: HYBN) today began a Phase I clinical trial in London of GEM(R)132, which the Company believes is the first advanced chemistry antisense compound administered to humans. This trial represents the first step in Hybridon s two pronged development of GEM132
Protein Design Halts One of Three Protovir Trials: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; MOUNTAIN VIEW, Calif., Aug. 14 /PRNewswire/ -- Protein Design Labs, Inc. (PDL) announced that the Studies of the Ocular Complications of AIDS (SOCA) group decided today to stop enrollment and treatment in the Phase II/III trial of PDL s PROTOVIR (TM) human anti- CMV antibody (MSL 109) as a supplemental treatment to
Immunomedics Awarded U.S. Patent for Therapeutic Conjugates of Toxins and Drugs; Immunomedics Invents New Targeted Therapies for Cancers and Infectious Diseases: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; MORRIS PLAINS, N.J., Aug. 14 /PRNewswire/ -- Immunomedics, Inc. (Nasdaq: IMMU) today announced the issuance of U.S. patent No. 5,541,297, creating new conjugates useful in cancer or infectious disease therapy. The patent extends Immunomedics U.S. patent portfolio to 32 and its foreign equivalents to over 100. The compa
Fifth Circuit Court of Appeals Vindicates Jackson National Life Insurance Company In Deramus Case: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; LANSING, Mich., Aug. 12 /PRNewswire/ -- Jackson National Life is pleased to report that the U.S. Court of Appeals for the Fifth Circuit has issued a ruling vindicating Jackson National s position in the suit filed by Jody Deramus. Mrs. Deramus brought suit against Jackson National in 1992, accusing it of breaching an a
Impact Of HIV/AIDS On Life Expectancy In The United States: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; CHICAGO, Aug. 7 /PRNewswire/ -- If we cured AIDS, heart disease or cancer, how would it affect life expectancy? A study by Dr. Dejian Lai, of the School of Public Health at the University of Texas, Houston, discussed at the Joint Statistical Meetings (Chicago -- August 3-8) gives some surprising answers. The potential
New Data Published in New England Journal of Medicine Suggest Clarithromycin is Effective in Prolonging Life of Aids Patients; Study Shows the Antibiotic Can Help AIDS Patients Live Longer: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; NASHVILLE, Tenn., Aug. 7 /PRNewswire/ -- A new study to be published in the August 8, 1996 issue of The New England Journal of Medicine shows clarithromycin (Biaxin(R)) prolongs life by reducing the incidence of Mycobacterium avium complex ( MAC ) infection in patients with advanced HIV infection. Mark Pierce, M.D.
New England Journal Of Medicine Study Shows Prophylaxis Of Disseminated Mycobacterium Avium Complex Is More Effective With Once-Weekly Azithromycin Than Daily Rifabutin In Patients With AIDS: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; SAN DIEGO, Calif., Aug. 7 /PRNewswire/ -- The University of California, San Diego, today issued the following: According to a study published in today s New England Journal of Medicine, once-weekly dosing of azithromycin is a simpler, more effective regimen than daily rifabutin (2 versus 14 tablets weekly) for the prev
VIRAMUNE(R) (Nevirapine) Now Commercially Available for the Treatment of HIV; First Non-nucleoside Available for use in Combination with Nucleosides: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; COLUMBUS, Ohio, Aug. 7 /PRNewswire/ -- Roxane Laboratories today announced that distribution has begun for VIRAMUNE(R) ( nevirapine ), the first drug in a new class of compounds called non-nucleoside reverse transcriptase inhibitors (NNRTI s). NNRTI s have a unique mechanism of action and a dis
Clinton Signs Bipartisan, Pro-Environment Drinking Water Bill: Support of Water Suppliers Key to Strong Public Health Protections: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; WASHINGTON, Aug. 6 /PRNewswire/ -- President Bill Clinton today signed into law the first piece of major environmental legislation sent to him by Congress in more than two years. The bill, reauthorizing the Safe Drinking Water Act, was the only environmental legislation to receive strong bipartisan support in Congress
SmithKline Beecham and Solvay Pharmaceuticals Join Forces To Expand Market Scope For Famvir For Treatment of Genital Herpes: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; ATLANTA and PHILADELPHIA, Aug. 5 /PRNewswire/ -- Solvay Pharmaceuticals, Inc. and SmithKline Beecham (SB) announced today they have established a co-promotion agreement to market SB s Famvir(R) (famciclovir), an antiviral agent that recently received U.S. Food and Drug Administration ( FDA ) clearance for treatment
The Liposome Company's ABELCET Approved in Greece For Treatment of Severe Systemic Fungal Infections: Approval Includes First-Line Treatment of Cryptococcal Meningitis: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; PRINCETON, N.J., Aug. 5 /PRNewswire/ -- The Liposome Company, Inc. (Nasdaq: LIPO, LIPOZ) has received marketing approval for ABELCET(R) (Amphotericin B Lipid Complex Injection) in Greece . The product was approved for the first-line treatment of cryptococcal meningitis, a relatively common fungal infection in A
New Standards To Control Threats To U.S. Blood Supply Are Released Today By Congress: Hepatitis C is a Major Issue: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; WHAT: A report calling for higher national standards to protect the nation s blood supply from infectious agents including the hepatitis C and HIV viruses and other blood-borne pathogens. WHO: Released by the House of Representatives Government Reform and Oversight Committee, and hepatitis C recommendations underscored
Female Condom Draws Interest At International AIDS Conference; Studies Find Acceptability High; Less Unprotected Sex When Female Condom Is Available: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; CHICAGO, Aug. 5 /PRNewswire/ -- More than 20 studies presented at the recent XI International Conference on AIDS involved the female condom, ranging from a strong supportive discussion by Dr. Christopher Elias of The Population Council at a plenary session, to Dr. Erica Gollub s oral presentation on the encouraging ini
SciClone Pharmaceuticals Announces Plan To File For Regulatory Approval Of Zadaxin(R) Thymosin Alpha 1 In Taiwan As A Treatment For Chronic Hepatitis B: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; SciClone Reports Statistically Significant Response to ZADAXIN Treatment in Meta-analysis of Completed Series of Hepatitis B Clinical Trials SAN MATEO, Calif., Aug 1 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN), an international biopharmaceutical company, today announced its plan to file for regulatory
Terrorism To Tornadoes: Emergency Physicians And Disaster Response: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; WASHINGTON, Aug 1 /PRNewswire/ -- What began as a typical weekday morning on a Tokyo subway in March 1995 quickly turned into a disaster as hundreds of commuters were exposed to a deadly vapor, known as sarin gas. This terrorist attack is the largest documented civilian exposure to a warfare nerve agent leading to 12 d
Lidak Pharmaceuticals Commences Additional Phase 3 Clinical Study Of Lidakol(R) For Treatment Of Oral Herpes: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; LA JOLLA, Calif., July 31 /PRNewswire/ -- LIDAK Pharmaceuticals (Nasdaq-NNM: LDAKA) announced that it has commenced the first of two additional Phase 3 clinical studies in the United States with n- docosanol 10% cream (LIDAKOL(R)) for the topical treatment of recurrent oral herpes (i.e., cold sores or fever blisters).
Rep. Tom Coburn, M.D. To Announce The Introduction Of A Comprehensive HIV Prevention Proposal Thursday, August 1: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; Rep. Tom Coburn, M.D. (R-OK) will announce the introduction of the HIV Prevention Act of 1996 at a press conference to be held Thursday, August 1. Rep. Coburn is a practicing physician and the author of the Baby AIDS law. Rep. Coburn will be joined by Americans for A Sound AIDS/HIV Policy (ASAP), the Independent Women
SmithKline Beecham And TheraTech Announce New Patch For Testosterone Replacement Therapy Now Available In The United Kingdom: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; PHILADELPHIA, and SALT LAKE CITY, Utah, July 31 /PRNewswire/ -- SmithKline Beecham (NYSE: SBH) and TheraTech, Inc. (Nasdaq: THRT) today announced that Andropatch(TM), a transdermal patch for the treatment of testosterone-deficient, hypogonadal men, has been approved for marketing by the regulatory authorities in the
Trinity Biotech Launches One Step HIV And Hepatitis Tests: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; DUBLIN, Ireland , July 30 /PRNewswire/ -- Trinity Biotech plc (Nasdaq: TRIBY) today announced the launch of two new rapid, one step tests for HIV and Hepatitis B. These tests are unique in that they require only one drop of either whole blood, serum or plasma and no other steps to determine the HIV or Hepatitis B statu
BASF Bioresearch And Ares-Serono Enter Manufacturing Agreement For Recombinant Human Growth Hormone: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; WORCESTER, Mass., and GENEVA, July 30 /PRNewswire/ -- BASF Bioresearch Corporation and Ares-Serono have signed an agreement for BASF to manufacture Ares-Serono s mammalian cell-derived recombinant human growth hormone (hGH) for commercial production, the companies announced today. In April the FDA issued an ap
EPA's Drinking Water Team Makes Recommendations To District: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; WASHINGTON, July 24 /PRNewswire/ -- A team of Environmental Protection Agency drinking water experts has been studying the District of Columbia s drinking water system for the last two weeks, and has developed a list of priorities for the District on how to improve drinking water quality. The team was dispatched to the
Access To Promising New AIDS Drug Therapies A Problem In Southern California: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; IRVINE, Calif., July 24 /PRNewswire/ -- At the Eleventh Annual International Conference on AIDS held in Vancouver, British Columbia during the second week of July, a number of promising new combination drug treatments were announced that, in some cases, greatly reduce or may potentially eradicate the Human Immune Defic
Epivir (Lamivudine; 3tc) Study Stopped; Results Show Significant Reduction In HIV Disease Progression Or Death: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; RESEARCH TRIANGLE PARK, N.C., July 23 /PRNewswire/ -- A study to determine the effect of the anti-HIV therapy Epivir (R) (lamivudine; 3TC ) on survival, delay in disease progression or both, has been stopped after an interim analysis of the data showed a 54 percent re
New Internet HIV/AIDS Continuing Medical Education Program Cornerstone For Online System Services' Business Strategy: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; DENVER, July 24 /PRNewswire/ -- With the introduction of an interactive online HIV/AIDS continuing medical education (CME) program for healthcare professionals, Internet solutions provider Online System Services (Nasdaq: WEBB) has helped to develop and launch a new healthcare industry strategy to deliver vital, real-ti
Vertex To Receive U.S. Patent Covering VX-478 To Treat HIV Infection And AIDS: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; CAMBRIDGE, Mass., July 24 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for Vertex s patent application covering VX-478 and related novel HIV protease inhibitors . Vertex
Roberts Pharmaceutical Corporation Prepares Canadian Launch Of Advantage 24; A Contraceptive Gel Currently Under U.N. Study For Prevention Of Sexually Transmitted Disease And HIV: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; EATONTOWN, N.J., JULY 24 /PRNewswire/ -- Roberts Pharmaceutical Corporation (Nasdaq: RPCX) announced today that inventory is in place for the near-term Canadian launch of Advantage 24 (R), a vaginally delivered contraceptive gel. Roberts obtained the exclusive Canadian rights to Advantage 24 from Columbia Laboratories,
CEL-SCI Corporation Purchases All Remaining Rights To HGP-30 AIDS Vaccine From Former Japanese Partner: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; ALEXANDRIA, Va., July 22 /PRNewswire/ -- CEL-SCI CORPORATION (Nasdaq: CELI/CELIW) today announces that it has purchased all remaining rights to the HGP-30 AIDS vaccine from Nippon Zeon Company, Ltd. of Japan for 45,000 shares of CEL-SCI common stock. This third and final transaction completes CEL-SCI s plan to bring in
Raspberries And Cyclospora: Guatemala Cooperating Fully: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; WASHINGTON, July 20 /PRNewswire/ -- The following release was issued today by the Guatemalan Berries Commission: Responding to an alleged connection between Guatemalan raspberries and outbreaks of cyclospora infection in the United States and Canada , we, the Guatemalan berry growers, are cooperating fully with Amer
AIDS In The Workplace Survey Is A `Wake-Up Call' For American Businesses; CDC National Survey Finds Both Good News and Challenges Ahead for AIDS Response: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; VANCOUVER, British Columbia, July 11 /PRNewswire/ -- Today, during a presentation at the XI International Conference on AIDS, the Centers for Disease Control and Prevention (CDC) will release a national survey of AIDS policies and education programs in the workplace. This survey revealed that nearly half of American wo
Data Suggest Possible Utility Of Investigational Three-Drug Combination For Treatment Of Primary HIV Infection: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; VANCOUVER, British Columbia, July 11 /PRNewswire/ -- Glaxo Wellcome today issued the following: Preliminary data from a small study suggest that treatment of patients with the triple drug combination of Epivir (R) (lamivudine;
Investigational Three-Drug Regimen Adds Further Support For Potential Benefits Of Combination Therapy: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; VANCOUVER, British Columbia, July 11 /PRNewswire/ -- Glaxo Wellcome today issued the following: Results of a small, open-label study suggest that the combination of Epivir (R) (lamivudine; 3TC )+Retrovir(R) (zidovudine
Italian Researchers Report Promising Results In Phase III Study Of Thymosin Alpha 1 As Immune System Enhancer: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; SAN MATEO, Calif., July 11 /PRNewswire/ -- SciClone Pharmaceuticals, Inc., (Nasdaq: SCLN) today reported that preliminary Phase III data being presented at the 11th International Conference on AIDS in Vancouver, provides further evidence that thymosin alpha 1 can influence the immune system in individuals. The findings
Researchers Recommend Combined Use Of Viral Load And Cd4 Counts In HIV Disease Management And Therapeutic Trials: First and Largest Study to Demonstrate that Combination is Strongest Indicator of Disease Progression: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; VANCOUVER, Britsh Columbia, July 11 /PRNewswire/ -- HIV-1 quantitation, or viral load, and CD4+T-cell counts, when used in combination, provide the most powerful indicator of risk of AIDS and death in HIV-infected individuals, according to new findings from the Multicenter AIDS Cohort Study (MACS) presented today at th
Norvir/Invirase AIDS Study Shows Promising Early Results; Collaborative Study Is First To Examine Dual Protease Inhibitor Combination: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; VANCOUVER, British Columbia, July 11 /PRNewswire/ -- A combination of Abbott Laboratories (NYSE: ABT) Norvir ( ritonavir ) and Hoffmann-LaRoche s Invirase (
New Research Uncovers Potential For More Effective Anti-HIV Therapies: Essential Role of Cyclophilin, Novel Non-Mutable Drug Target Discovered: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; VANCOUVER, British Columbia, July 10 /PRNewswire/ -- Research presented today at the XI International Conference on AIDS shows how new therapies aimed at the cellular protein cyclophilin may be instrumental in preventing the human immunodeficiency virus (HIV) from infecting new cells. This finding by The Picower Instit
Norvir Reduces Long-Term Cost Of AIDS Care And Improves Quality Of Life: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; VANCOUVER, British Columbia, July 10 /PRNewswire/ -- In research presented here today at the 11th International Conference on AIDS, economic modeling based on outcomes data and medical care costs in both the United States and United Kingdom demonstrates that Abbott Laboratories
STD Control Plays Important Role In Reducing The Spread Of HIV: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; VANCOUVER, British Columbia, July 10 /PRNewswire/ -- In a panel discussion at the International AIDS Conference today, researchers stress the important link between the treatment of other sexually transmitted diseases and reduction in the spread of HIV. Judith Wasserheit, M.D., M.P.H., cites the results of a community-
Aztec Established As The AZT Standard Of The Future: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; ENGLEWOOD, Colo., July 10 /PRNewswire/ -- Verex Laboratories, Inc. (OTC BULLETIN BOARD: VRXL) announced that significant new scientific information was released today at the XI International Conference on AIDS in Vancouver, British Columbia, concerning its controlled release AZT formulat
Investigators Present Interim Phase I/II Data At International AIDS Conference On Alrt1057 Topical Retinoid Gel In Kaposi's Sarcoma; 30% Of Patients Achieve Partial or Complete Response: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; VANCOUVER, British Columbia, July 8 /PRNewswire/ -- Madeleine Duvic, MD, Chief of Dermatology at The University of Texas -- Houston Medical School, today reported to the medical scientific community at the XIth International AIDS Conference interim results of Phase I/II clinical trials of ALRT1057 (9-cis-retinoic acid)
Triple Therapy In Previously Untreated Patients Reduces Viral Load Below Limit Of Detection; New Data Shows VIRAMUNE, First Drug in Non-Nucleoside Class of Agents, Effective Through One Year: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; VANCOUVER, British Columbia, July 9 /PRNewswire/ -- A triple combination therapy including VIRAMUNE (R)( nevirapine ) demonstrated a sustained twelve month reduction in viral load below the limit of detection in Trial BI ( Boehringer Ingelheim )
Durex Survey Shows U.S. Below Global Average For Sex Education In Schools: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; VANCOUVER, British Columbia, July 9 /PRNewswire/ -- Despite a revolution in sex education since the AIDS epidemic began, the results of the Durex Global Survey(l) released at the XI International Conference on AIDS in Vancouver show that school-based sex education in the U.S. lags far behind other countries as the prim
The Immune Response Corporation Enters Into Collaboration With Bayer Corporation: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; CARLSBAD, Calif., and PITTSBURGH, July 9 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) and Bayer Corporation announced today that they have entered into a collaboration agreement to develop a gene therapy product for the treatment of hemophilia A. Bayer Corporation, a market leader in the treatment of
Latest Information On Clinical Trials Of Thalidomide For AIDS-Related Complications Available: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; FOR: Editors and correspondents covering the 11th International Conference on AIDS, Vancouver, July 7-11, 1996. RE: Current clinical research into new applications of thalidomide (SYNOVIR(TM)) for several major complications of AIDS, including cachexia (or wasting disease, a complication suffered by an estimated
Rotary And Un Join Forces To Combat AIDS; Young People Tapped As Part Of The Solution: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; VANCOUVER, Canada , July 8 /PRNewswire/ -- Luis Vicente Giay, President of Rotary International and Peter Piot, Executive Director of the United Nations Programme on HIV/AIDS ( UNAIDS ) today signed an agreement pledging their organizations to work together to save the lives of millions of young people who are at risk
Viracept(TM) Proves Effective In Combination Therapy: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; HOUSTON, July 8 /PRNewswire/ -- Data will be presented this week at the Eleventh International Conference on AIDS in Vancouver that reinforces the activity and safety of VIRACEPT(TM) (nelfinavir mesylate), when used in combination therapy . Joseph Gathe, M.D., Montrose Clinic - Houston Clinical Research, Houston, prese
Global Effort To Develop AIDS Vaccine Launched: Industry, Governments And Non-Profits Worldwide To Join The Search For Most Effective Way To Stop The Epidemic: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; VANCOUVER, British Columbia, July 7 /PRNewswire/ -- Issuing an urgent global call to marshall world resources to develop an AIDS vaccine, the International AIDS Vaccine Initiative (IAVI) today announced initial multi-million dollar funding to help accelerate AIDS vaccine research and development worldwide. A vaccine is
International AIDS Conference Opens With Warning On Drug Resistance And Data On A New Solution: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; VANCOUVER, B.C., July 7 /PRNewswire/ -- Leading AIDS researchers meeting in Vancouver, B.C. on the eve of the official opening of the XI International Conference on AIDS, discussed the growing problem of drug resistance in patients with fungal infections, one of the most common opportunistic infections affecting AIDS p
Durex Survey Shows Taking Precautions Against AIDS Is Of Minor Importance In The U.S.: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; VANCOUVER, British Columbia, July 8 /PRNewswire/ -- Despite the current AIDS epidemic, the results of a recent global survey released at the XI International Conference on AIDS show that U.S. respondents view taking precautions against AIDS as the least important factor when making love. Among the 10,000 sexually activ
Scientists Discover Second Chemokine Coreceptor Used By AIDS Virus To Infect Immune System Cells: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; CAMBRIDGE, Mass., July 8 /PRNewswire/ -- Scientists at LeukoSite Inc., the Dana-Farber Cancer Institute and Children s Hospital have demonstrated that a chemokine coreceptor named CCR3 is used by the AIDS virus to enter and infect certain white blood cells, LeukoSite announced today. The research, reported in the June
Community Based Research Confirms Viracept Safety And Activity: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; SAN FRANCISCO, July 8 /PRNewswire/ -- Data presented today at the Eleventh International Conference on AIDS by Marcus Conant, M.D., Conant Medical Group, San Francisco, substantiate the safety and antiviral activity of VIRACEPT(TM) (nelfinavir mesylate), Agouron Pharmaceutical s HIV protease inhibitor. Dr. Conant studi
Investigators Present Results Of Viracept Studies At International AIDS Meetings: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; LA JOLLA, Calif., July 8 /PRNewswire/ -- Agouron Pharmaceuticals, Inc., (Nasdaq-NNM: AGPH) today summarized reports of recent results from open label clinical studies of the investigational HIV protease inhibitor VIRACEPT(TM) (nelfinavir mesylate, formerly AG1343). The results include further evidence that VIRACEPT sha
Nelfinavir In Combination With AZT And 3tc Result In Aviremia: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; NEW YORK, July 8 /PRNewswire/ -- Martin Markowitz, M.D., Staff Investigator at The Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York, will present data this week at the Eleventh International Conference on AIDS that confirm undetectable levels of HIV-RNA in plasma as well as negative PBMC c
Triple Therapy Benefits With Norvir Sustained At 60 Weeks; Open-Label Trial Permits Rapid Assessment Of Combined Regimens: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; VANCOUVER, July 8 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) protease inhibitor Norvir ( ritonavir ), in combination with the nucleoside analogues AZT and
Elizabeth Taylor To Speak During International AIDS Conference In Vancouver; Taylor Will Address Aids Community At AmFAR's July 8 Reception At Vancouver Art Gallery: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; NEW YORK, July 3 /PRNewswire/ -- Elizabeth Taylor, Founding National Chairman of the American Foundation for AIDS Research ( AmFAR ) and longtime advocate for people with AIDS, will travel to Vancouver to attend the XI International Conference on AIDS. The actress will co- host AmFARs July 8 reception with Dr. Mathilde
Study Shows New Treatment For Recurrent Genital Herpes Effective Against All Symptoms With Convenient Twice-Daily Dose: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; VANCOUVER, B.C., July 3 /PRNewswire/ -- According to a study in this week s issue of The Journal of the American Medical Association (JAMA), a twice-daily dose of Famvir(R) (oral famciclovir, SmithKline Beecham) significantly reduced all symptoms of recurrent genital herpes in immunocompetent patient
MDCH Issues HIV Home Kit Recommendations: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; LANSING, Mich., June 25 /PRNewswire/ -- The Michigan Department of Community Health (MDCH) today issued some early advice for use of a new home blood collection kit that can show whether someone is infected with the virus that causes AIDS. The test may be available in Michigan as early as 1997. More than 99 percent acc
Voter Support For Family Planning Reaches Record Levels; New Poll Shows 90 Percent Of Americans Favor Access To Family Planning: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; WASHINGTON, June 25 /PRNewswire/ -- Legislators who oppose access to family planning are grossly out of touch with the American people, a new poll reveals. Family planning works to prevent unintended pregnancies and HIV/AIDS, and the American people know it, said Planned Parenthood Federation of America President Glori
Drinking Water Bill Clears House With Broad Bipartisan Support; Water Suppliers Applaud Better Public Health Protections: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; WASHINGTON, June 25 /PRNewswire/ -- The American Water Works Association (AWWA) endorses the Safe Drinking Water Act reauthorization bill (H.R. 3604), which was passed by unanimous voice vote in the House today. The bill is unique among the environmental legislation that has been acted upon by the House this year in th
ADA Takes Action On Two HIV Fronts: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; CHICAGO, June 24 /PRNewswire/ -- In its ongoing effort to monitor HIV issues that affect dentistry, the American Dental Association (ADA) recently took action on both scientific and legal issues. The ADA s council on Scientific Affairs completed a review of recent scientific literature on infection control and reiterat
Neozyme II Corporation And NABI Discontinue Phase II Clinical Trial Of HyperGAM+CF: Interim Results Do Not Demonstrate Efficacy: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; BOCA RATON, Fla., June 24 /PRNewswire/ -- Neozyme II Corporation (Nasdaq: NIIUF) and NABI (Nasdaq: NABI) announced today the halt of their Phase II clinical trial for HyperGAM+(TM)CF (Immune Globulin Intravenous [Human] [Pseudomonas aeruginosa]), for the treatment of severe Pseudomonas lung infections in Cystic Fibrosi
Crypto-Free Drinking Water Removes Fear Of Turning On The Tap (Municipalities Can Advise Residents to Drink Water With Confidence): PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; MILWAUKEE, June 24 /PRNewswire/ -- In 1993, when hundreds of thousands of Milwaukee residents became ill and a number of deaths resulted from cryptosporidium infected water, Tom Pokorsky s jaw set. Our assumption is that safe drinking water should be a perfectly reasonable expectation, says Pokorsky, president and chi
New International Association Provides Evidence Of Cortisol's Major Role In AIDS And Other Diseases: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; PARIS, June 21 /PRNewswire/ -- Researchers from Europe and the US gathered here today to launch the International Association of Researchers in Cortisol and Anti-Cortisols (IARCA) and present new findings showing the negative causal effect of cortisol in diseases for which current treatments still remain unsatisfactory
The Immune Response Corporation Granted Patent In Finland On HIV Technology: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; CARLSBAD, Calif., June 18 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that it has received a patent from Finland on its core HIV technology. This patent, issued to inventors Jonas Salk, M.D. and Dennis J. Carlo Ph.D., has been licensed to the company and covers The Immune Response Cor
Scientists And Patient Advocates Denounce Animal Rights Movement: Foundation for Biomedical Research (FBR) Releases Endangered Cures Report & AIDS Consensus Letter; Cites `Life-Threatening' Consequences as Animal Rights Week Begins: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; WASHINGTON, June 17 /PRNewswire/ -- On the eve of World Animal Awareness Week, scientists and patient advocates joined forces today to highlight specific areas of research that are currently endangered due to the advancement of the animal rights movement, and its opposition to the use of laboratory animals in all medic
Pharmacyclics' Photodynamic Therapy Agent Lu-Tex Is Well Tolerated And Demonstrates Activity In A Multicenter Phase I Cancer Trial: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; SUNNYVALE, Calif., June 17 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today the interim results of a Phase I clinical trial of its photosensitizer lutetium texaphyrin (Lu-Tex). The findings were presented yesterday at the annual meeting of the American Society for Photobiology in Atlanta. The study in
FDA PANEL RECOMMENDS ACCELERATED APPROVAL OF NEW AIDS DRUG Represents new treatment option for combination therapy: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; Silver Spring, MD -- June 10, 1996 -- The Antiviral Drugs Advisory Committee to the U.S. Food and Drug Administration ( FDA ) on Friday voted to recommend that the agency grant accelerated approval for VIRAMUNE. ( nevirapine ) in combination with nucleoside analogues for treating human immunodeficiency virus (H
Illinois Masonic Medical Center Offers Newly FDA-Approved Test For HIV: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; CHICAGO, June 6 /PRNewswire/ -- This week, the Food and Drug Administration approved a new test to help determine how fast an individual s infection with HIV is progressing to AIDS. Illinois Masonic Medical Center (IMMC) is the only hospital in the Chicago area and one of the first medical centers in the Midwest to off
Transportation Services Provided For Persons With HIV/AIDS: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; PHILADELPHIA, June 6 /PRNewswire/ -- Through the direct efforts and collaboration of Thrift for AIDS and the Philadelphia AIDS Consortium, the much needed program providing transportation, Transport for Access, to persons living with HIV and AIDS in the greater Philadelphia area is moving forward. Transport for Access
Study In The New England Journal Of Medicine Shows Cytovene Reduces Risk Of CMV Disease In People With AIDS; Data Indicate Prophylaxis Reduces Risk By 49 Percent: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; NUTLEY, N.J., June 6 /PRNewswire/ -- Prophylaxis with oral Cytovene(R) (ganciclovir capsules) significantly reduces the risk of cytomegalovirus ( CMV ) disease in people with advanced AIDS, according to results of a study published today in The New England Journal of Medicine. A 49 percent reduction in the risk of CM
Abelcet Granted Approval In Sweden For Treatment Of Severe Invasive Fungal Infections: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; PRINCETON, N.J., June 6 /PRNewswire/ -- The Liposome Company, Inc. (Nasdaq: LIPO and LIPOZ) has received marketing approval for ABELCET(R) (Amphotericin B Lipid Complex Injection) in Sweden . The approved indication is for the treatment of severe, invasive, fungal infections in patients who have not responded to conven
Unimed Pharmaceuticals Shares Plan For Growth At Cruttenden Roth HealthCare Conference: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; CRUTTENDEN ROTH, HEALTHCARE GROWTH STOCK CONFERENCE, NEW YORK, June 6 /PRNewswire/ -- Unimed Pharmaceuticals, Inc. (Nasdaq: UMED) President and CEO Stephen M. Simes shared the company s progress on its strategic plan at today s Cruttenden Roth Healthcare Growth Stock Conference. Since the current management began leadi
VA Doctor Says He Is Developing AIDS Cure While Helping Military Veterans: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; LAS VEGAS, June 5 /PRNewswire/ -- Because his 14-year-old son died of AIDS caused by a tainted blood transfusion, a Veterans Administration doctor says he is working hard to develop what he believes may be a cure for the fatal disease. But life can be funny, and while he was working on an AIDS cure, he says he develope
Alpha-Beta Announces Discovery Of Novel Receptor For Priming Of Human Immune Cell Defenses: Findings Elucidate Mechanism of Action for Lead Product: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; WORCESTER, Mass., June 5 /PRNewswire/ -- Alpha-Beta Technology, Inc. (Nasdaq: ABTI) announced today that its scientists in collaboration with researchers at the Worcester Polytechnic Institute, The Center for Blood Research at Harvard Medical School, and the University of California at Irvine, have identified a novel r
National Survey Conducted In Fifteen Cities And Seven Languages Reveals Details Of A Changing And Provocative America: 1996 MSR&C Ethnic Market Report Provides a Clear, Concise View of African Americans, Anglos, Asian Americans and Hispanics: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; WASHINGTON, D.C., June 4 /PRNewswire/ -- As a result of 5,000 interviews conducted in fifteen cities and seven languages, Market Segment Research & Consulting (MSR&C) has released the 1996 MSR&C Ethnic Market Report, the most comprehensive report to date detailing the demographics, consumer behavior, media
(PR) Amplicor HIV-1 Monitor(TM) Test First To Receive FDA Approval For Marketing; Test Measures Quantity of HIV-1 RNA in the Blood; Roche Offers Free Baseline Testing to HIV-Positive Patients: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; BRANCHBURG, N.J., June 3 /PRNewswire/ -- The U.S. Food and Drug Administration ( FDA ) today approved for marketing Roche Molecular Systems (RMS) AMPLICOR HIV-1 MONITOR(TM) Test, the first test to accurately and precisely measure quantities of HIV-1 RNA in the blood (viral load ). Using polymerase chain reaction (PCR)
Cel-SCI's HGP-30 AIDS Vaccine Shows Significant Protection Against HIV Challenge: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; ALEXANDRIA, Va., June 3 /PRNewswire/ -- CEL-SCI CORPORATION (Nasdaq-NNM: CELI) and the University of Nebraska Medical Center today announce the scientific presentation of results obtained with CEL-SCI s HGP-30 AIDS vaccine by Dr. James E. Talmadge of the University of Nebraska. He reported that 78% of SCID mice who had
Air Methods Corporation Announces Participation In Launch Of Universal Health Card: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; DENVER, May 31 /PRNewswire/ -- Air Methods Corporation (Nasdaq-NNM: AIRM) announced today at a press conference held at 11:30 a.m. EST at the Grand Ballroom, The Plaza Hotel, New York City, that it had acquired a five percent interest in EMX Global Emergency Services ( EMX ), which today launched The EMX Card -- the na
Oral Cytovene Shows Benefit For Prevention Of CMV Disease In Liver Transplant Recipients: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; DALLAS, May 29 /PRNewswire/ -- Data presented for the first time today suggest that oral ganciclovir (Cytovene(R) capsules) can help prevent potentially life-threatening cytomegalovirus ( CMV ) disease in liver transplant recipients. Data from study GAN 040, Efficacy and Safety of Oral Ganciclovir in the Prevention of
Four HealthCare Companies Formally Offer To Settle U.S. Hemophilia Litigation: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; NEW YORK, May 29 /PRNewswire/ -- Alpha Therapeutic Corporation, Armour Pharmaceutical Company, Baxter Healthcare Corporation and Bayer Corporation, four companies that process and distribute plasma-protein therapies for treatment of hemophilia, announced today that they have made a formal offer of $640 million intended
New Lipid Drugs Offer Significant Advance In Treatment Of Fungal Infections A Novel Approach to Fight Deadly Infections That Strike AIDS and Cancer Patients: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; PRINCETON, N.J., May 29 /PRNewswire/ -- New lipid preparations of the mainstay antifungal agent amphotericin B are an important contribution to the treatment of often fatal fungal infections, according to a new report published in a supplement to the May issue of Clinical Infectious Diseases. The authors say these agen
The Immune Response Corporation And The National Institutes Of Health Begin First Pediatric Clinical Trial Of Remune(TM) HIV Therapy: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; CARLSBAD, Calif., May 29 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today the start of the first clinical trial in children using REMUNE, an HIV therapy being developed by Immune Response. This Phase I trial, which is being conducted in collaboration with the National Institutes of Health
Isis And Collaborators Demonstrate Decrease In Inflammatory Response Via Icam-1 Inhibition In Mouse Model Of Pneumonia: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; CARLSBAD, Calif., May 28 /PRNewswire/ -- Isis Pharmaceuticals (Nasdaq: ISIP), in collaboration with Claire Doerschuk at the Harvard School of Public Health and collaborators at several academic research laboratories, have demonstrated inhibition of intercellular adhesion molecule-1 (ICAM-1) with an antisense oligonucle
Oncogene Science, Inc. Receives Sbir Phase II Grant For HIV-1 Research: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; UNIONDALE, N.Y., May 24 /PRNewswire/ -- Oncogene Science, Inc. (Nasdaq: ONCS) announced today that it has received a Small Business Innovative Research (SBIR) Phase II grant in the amount of approximately $631,000 to identify novel inhibitors of a protein thatis critical to replication of the HIV-1 virus. The principal
CPMP Grants Scientific Approval To Abbott's Norvir For Treatment Of HIV Infection: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; ABBOTT PARK, Ill., May 24 /PRNewswire/ -- The European Agency for the Evaluation of Medicinal Products (EMEA) has granted within its scientific Committee for Proprietary Medicinal Products (CPMP) a positive scientific opinion on the granting of a European marketing authorization to Abbott s HIV protease inhibitor
Research Confirms HIV Plasma Viral Load Can Predict The Risk Of AIDS And Death In HIV-Infected Individuals; Study Indicates That Viral Load Measurements Provide Physicians with a Powerful Prognostic Tool: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; PITTSBURGH, May 23 /PRNewswire/ -- Viral load, the amount of human immunodeficiency virus (HIV) RNA in the plasma of infected individuals, can accurately predict how quickly people with HIV infection will progress to AIDS and, ultimately, their survival, according to a study published in the May 24, 1996 issue of Scien
Clinton Affirms Medicaid Commitment To People With Disabilities At Annual Conference On Disability: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; DETROIT, May 24 /PRNewswire/ -- The following was released by the President s Committee on Employment of People with Disabilities: President Clinton today called for expanding opportunities for every American who is willing to take responsibility for making the most of his or her God-given abilities, and announced his
Cubist Pharmaceuticals Inc. Receives Two Sbir Phase II Grants Totaling $1.3 For The Development Of Novel Anti-Infectives: PR Newswire, 810 Seventh Avenue, New York, NY 10019; CAMBRIDGE, Mass., May 24 /PRNewswire/ -- Cubist Pharmaceuticals, Inc. of Cambridge, Massachusetts has been awarded two separate SBIR Phase II grants to develop antimicrobial agents for the treatment of pneumonia caused by Pneumocystis carinii and for the treatment of Mycobacterium tuberculosis infections. These gr
La Jolla Pharmaceutical Presents Additional Phase II Results At Immunology Conference: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; SAN DIEGO, May 23 /PRNewswire/ -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that Stephen M. Coutts, Ph.D., the Company s Executive Vice President of R & D, will present data on LJP 394, a drug candidate for lupus, at the International Conference on B Lymphocytes and Autoimmunity held in Prague,
The Immune Response Corporation's Licensed Gene Delivery Technology Receives United States Patent: PR Newswire, 810 Seventh Avenue, New York, NY 10019 -; CARLSBAD, Calif., May 23 /PRNewswire/ -- The Immune Response Corporation (Na